Recent Fluvoxamine COVID benefits discovered using Cytel-designed platform trial
Using Cytel’s expertise, the TOGETHER Trial simultaneously tests multiple repurposed therapies WALTHAM, Mass.–(BUSINESS WIRE)–The recently announced benefits of fluvoxamine, an inexpensive drug currently approved as an antidepressant, for treating COVID-19, were confirmed thanks to a platform research study, the TOGETHER Trial, which included key design and implementation contributions from Cytel researchers. According to research study […]